Conexeu Sciences Inc. News Releases

Conexeu Sciences Commences Trading on Nasdaq Under Ticker Symbol "CNXU"

Thu, 21 May 2026 12:02:00 -0400

Public listing marks key milestone as Conexeu advances proprietary CXU(TM) platform and vision for regenerative medicine focused on biological restoration Reno, Nevada--(Newsfile Corp. - May 21, 2026) - Conexeu Sciences Inc. (Nasdaq: CNXU) ("Conexeu" or the "Company"), a biotechnology company advancing tissue regeneration, announced it has officially commenced trading on the Nasdaq today under the ticker symbol "CNXU." The Company currently has 25,269,996 shares on an issued and outstanding...

Conexeu Sciences Advances 3D Biofabricated Matrix to Move Breast Reconstruction Beyond Implants

Tue, 19 May 2026 08:30:00 -0400

Conexeu's B.R.E.A.S.T.™ was developed using the Company's proprietary CXU™ regenerative tissue platform to support gradual tissue remodelingDesigned as a resorbable, bioregenerative tissue matrix rather than a permanent implant prosthesisTechnology informed by more than a decade of preclinical research and proprietary extracellular matrix development Reno, Nevada--(Newsfile Corp. - May 19, 2026) - Conexeu Sciences Inc. ("Conexeu" or the "Company"), a biotechnology company advancing tissue...

Conexeu Sciences Unveils Defining Commitment: Architecting Bioregeneration(TM)

Thu, 14 May 2026 08:30:00 -0400

Conexeu Sciences has made a deep commitment to the research, development, and infrastructure required to lead the next era of regenerative medicine, bringing together the Company's platform science and multi-application vision under one unifying idea, drawn from the discipline of architecture itself. Reno, Nevada--(Newsfile Corp. - May 14, 2026) - Conexeu Sciences Inc. (the "Company" or "Conexeu") a medical device company advancing regenerative medicine through its patented bioregenerative...

Conexeu Sciences Signals a Major Breakthrough in 'Personalized Human Tissue Creation'

Thu, 20 Nov 2025 09:00:00 -0500

Reno, Nevada--(Newsfile Corp. - November 20, 2025) - Conexeu Sciences Inc. ("Conexeu" or the "Company"), a biotechnology innovator redefining regenerative medicine through a next-generation collagen-based platform, is pleased to announce that it has achieved a defining milestone in regenerative medicine with the first ever 3D-printed structures made entirely from its patented, functional extracellular matrix (ECM). Using its patented CXU™ platform, the Company has printed bovine-derived...

Conexeu Sciences Inc. Expands Board of Directors with the Appointments of Dr. Aaron Farberg and Dr. Sebastian Purcell

Wed, 05 Nov 2025 07:00:00 -0500

Reno, Nevada--(Newsfile Corp. - November 5, 2025) - Conexeu Sciences Inc. ("Conexeu" or the "Company"), a biotechnology innovator redefining regenerative medicine through a next-generation collagen-based platform, today announced the appointments of Aaron Farberg, M.D. and Sebastian Purcell, Ph.D. to its Board of Directors. The additions bring together leading expertise from the worlds of medicine, science, and ethics-driven innovation as Conexeu advances its mission to pioneer collagen-based...

Conexeu Sciences Appoints Miles Harrison as President & Chief Executive Officer, to Shape the Future of True Tissue Regeneration

Mon, 03 Nov 2025 07:00:00 -0500

Reno, Nevada--(Newsfile Corp. - November 3, 2025) - Conexeu Sciences Inc. ("Conexeu" or the "Company"), a pre-commercial biotechnology company redefining regenerative medicine through next-generation collagen science, announces the appointment of Miles D. Harrison as President & Chief Executive Officer of the Company. He has also been appointed to the Company's Board of Directors.At Conexeu, Miles will lead the Company's next phase of growth, advancing its first-in-class collagen platform for...

Conexeu Sciences Closes Maximum $5M Reg CF Financing

Thu, 16 Oct 2025 09:01:00 -0400

Reno, Nevada--(Newsfile Corp. - October 16, 2025) - Conexeu Sciences Inc. (the "Company" or "Conexeu") a biotechnology company revolutionizing tissue regeneration, is pleased to announce the completion of its $5 million Regulation Crowdfunding (Reg CF) financing. Conexeu secured commitments in excess of $5 million in less than two weeks from the date of launching the financing through the Equifund platform. Conexeu Chief Executive Officer, Jeff Sharpe, stated, "This milestone highlights the...